TopNewsOn
Health

STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics

Adam Feuerstein·STAT News·November 15, 2026

The FDA has rejected ivonescimab, a treatment for a type of lung cancer developed by U.S. biotech Summit Therapeutics and the Chinese drugmaker Akeso. 

Read the full story at STAT News →
STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics — TopNewsOn